Compare TWST & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWST | GKOS |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 10.6B |
| IPO Year | 2018 | 2015 |
| Metric | TWST | GKOS |
|---|---|---|
| Price | $163.58 | $161.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $46.88 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 1.6M | 575.0K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $376,572,000.00 | ★ $507,442,000.00 |
| Revenue This Year | $18.91 | $23.32 |
| Revenue Next Year | $15.07 | $27.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 20.32 | ★ 32.33 |
| 52 Week Low | $23.30 | $73.16 |
| 52 Week High | $163.70 | $191.62 |
| Indicator | TWST | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 70.79 | 35.52 |
| Support Level | $39.81 | $145.78 |
| Resistance Level | N/A | $161.53 |
| Average True Range (ATR) | 8.92 | 6.67 |
| MACD | 1.47 | -2.84 |
| Stochastic Oscillator | 94.55 | 6.00 |
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.